Ceftobiprole Noninferior to Daptomycin for Complicated Staph Infection
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 4, 2023 -- For patients with complicated Staphylococcus aureus bacteremia, ceftobiprole is noninferior to daptomycin for overall treatment success, according to a study published online Sept. 27 in the New England Journal of Medicine.
Thomas L. Holland, M.D., from Duke University in Durham, North Carolina, and colleagues conducted a phase 3 noninferiority trial involving adults with complicated S. aureus bacteremia who were randomly assigned to receive ceftobiprole or daptomycin plus optional aztreonam at the discretion of the investigators (189 and 198 patients, respectively). The primary outcome was overall treatment success 70 days after randomization, with a noninferiority margin of 15 percent.
The researchers found that 69.8 and 68.7 percent of the patients in the ceftobiprole and daptomycin groups, respectively, had overall treatment success (adjusted difference, 2.0 percentage points; 95 percent confidence interval, −7.1 to 11.1). In key subgroups and with respect to secondary outcomes, including mortality and the percentage of patients with microbiologic eradication, the findings were consistent between the groups. Adverse events were reported in 63.4 and 59.1 percent of patients receiving ceftobiprole and daptomycin, respectively; serious adverse events were reported in 18.8 and 22.7 percent.
"In addition, microbiologic eradication, relapse of bacteremia, and new or worsening S. aureus bacteremia complications were similar in the two trial groups, findings that further indicate that ceftobiprole was not less effective than daptomycin," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Basilea Pharmaceutica International, which markets ceftobiprole and partially funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Inappropriate Antibiotic Prescribing Identified in Safety-Net Populations
THURSDAY, May 30, 2024 -- Inappropriate antibiotic prescribing is common with or without a plausible antibiotic indication, and inappropriate prescribing is also common in U.S...
Disparities Seen in Carbapenem-Resistant Enterobacterales Bloodstream Infection Outcomes
TUESDAY, May 14, 2024 -- Black female patients hospitalized for carbapenem-resistant Enterobacterales (CRE) bloodstream infections (BSI) face increased 30-day mortality, according...
Following Drop After COVID-19 Onset, Inappropriate Antibiotic Prescribing Is Up
WEDNESDAY, May 1, 2024 -- There was an initial decrease in inappropriate antibiotic prescriptions following onset of COVID-19, followed by an increase, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.